631 related articles for article (PubMed ID: 28447218)
1. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P; Whitworth P; Baron P; Rotkis MC; Mislowsky AM; Richards PD; Murray MK; Pellicane JV; Dul CL; Nash CH; Stork-Sloots L; de Snoo F; Untch S; Lee LA
Ann Surg Oncol; 2017 Sep; 24(9):2539-2546. PubMed ID: 28447218
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
[TBL] [Abstract][Full Text] [Related]
3. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Whitworth P; Stork-Sloots L; de Snoo FA; Richards P; Rotkis M; Beatty J; Mislowsky A; Pellicane JV; Nguyen B; Lee L; Nash C; Gittleman M; Akbari S; Beitsch PD
Ann Surg Oncol; 2014 Oct; 21(10):3261-7. PubMed ID: 25099655
[TBL] [Abstract][Full Text] [Related]
5. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
6. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC; van der Voort A; van Ramshorst MS; Sanders J; Vonk S; Horlings HM; Siesling S; de Munck L; van Leeuwen AE; Kleijn M; Mittempergher L; Kuilman MM; Glas AM; Wesseling J; Lips EH; Sonke GS
Breast Cancer Res; 2023 Jun; 25(1):71. PubMed ID: 37337299
[TBL] [Abstract][Full Text] [Related]
7. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
8. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
9. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
10. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
[TBL] [Abstract][Full Text] [Related]
11. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Nitz UA; Gluz O; Christgen M; Grischke EM; Augustin D; Kuemmel S; Braun M; Potenberg J; Kohls A; Krauss K; Stefek A; Schumacher C; Forstbauer H; Reimer T; Fischer H; Liedtke C; Wuerstlein R; Schumacher J; Kates R; Kreipe H; Harbeck N
Ann Oncol; 2017 Nov; 28(11):2768-2772. PubMed ID: 28945833
[TBL] [Abstract][Full Text] [Related]
12. Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Baron P; Beitsch P; Boselli D; Symanowski J; Pellicane JV; Beatty J; Richards P; Mislowsky A; Nash C; Lee LA; Murray M; de Snoo FA; Stork-Sloots L; Gittleman M; Akbari S; Whitworth P
Ann Surg Oncol; 2016 May; 23(5):1522-9. PubMed ID: 26714960
[TBL] [Abstract][Full Text] [Related]
13. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
Murthy RK; Raghavendra AS; Hess KR; Fujii T; Lim B; Barcenas CH; Zhang H; Chavez-Mac-Gregor M; Mittendorf EA; Litton JK; Giordano SH; Thompson AM; Valero V; Moulder SL; Tripathy D; Ueno NT
Clin Breast Cancer; 2018 Dec; 18(6):e1283-e1288. PubMed ID: 30077429
[TBL] [Abstract][Full Text] [Related]
18. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
20. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
